Timing of antiretroviral treatment initiation and seropositivity to measles virus among children living with HIV in rural Zambia

This study of children living with HIV in rural Zambia found that low measles antibody levels persisted regardless of whether antiretroviral therapy was initiated before or after nine months of age, supporting the recommendation for revaccination to ensure adequate immunity.

The Gist

The Big Picture: A Broken Shield and a Delayed Repair

Imagine your body's immune system is a castle wall designed to keep out invaders like the measles virus. For children living with HIV, this wall is cracked and crumbling. They can't build it back up well on their own.

Doctors have a magic tool called cART (antiretroviral therapy) that stops the HIV from breaking the wall further and helps the body start repairing itself. However, there's a catch: cART fixes the bricks, but it doesn't automatically repaint the "Measles Defense" sign on the wall.

This study asked a crucial question: If we start fixing the castle wall (cART) before we try to paint the Measles sign (vaccination), does the sign stick better?

The Setting: Rural Zambia

The researchers looked at children in rural Zambia. In this area, measles is a real threat. The standard rule is to give the measles vaccine (the "Measles Sign") when a child turns 9 months old.

In the past, many children got HIV treatment after they were already sick or older. But now, doctors are trying to start treatment immediately, even for babies just a few months old. The question was: Does starting treatment this early help the child's body remember the measles vaccine better?

The Experiment: Three Groups of Kids

The researchers divided the children into three groups based on when they started their HIV treatment:

1. The "Super Early" Group: Started treatment between 0–8 months (before the usual vaccine age).
2. The "Standard" Group: Started treatment between 9–23 months (around the time of the first vaccine).
3. The "Late" Group: Started treatment between 24–59 months (long after the first vaccine).

They compared these kids to healthy children who didn't have HIV.

The Findings: The "Leaky Bucket" Problem

Here is what they discovered, using a simple analogy:

1. The "Leaky Bucket" Analogy
Imagine the measles vaccine fills a bucket with water (antibodies) to protect the child.

• Healthy Kids: Their buckets are solid. They get filled, and the water stays there for years.
• Kids with HIV: Their buckets have holes in the bottom. Even if you fill them up with the vaccine, the water leaks out very fast.

The Result:

• Low Protection: Only about 1 in 3 children with HIV had enough "water" (antibodies) to be protected against measles, even after starting treatment.
• No Magic Fix: It didn't matter if they started treatment before or after the vaccine. The "leaky bucket" problem persisted. Starting treatment early helped their general health, but it didn't stop the measles protection from leaking away.
• The Comparison: Healthy children in the same area had protection rates of 60% to 80%. The children with HIV were significantly more vulnerable.

2. The "Fast-Forward" Decay
The study tracked these kids over time. They found that for children with HIV, the protection didn't just leak; it drained very quickly.

• For healthy kids, the protection lasts for many years.
• For kids with HIV, the protection often disappeared completely within 2 to 3 years. It's like filling a bucket with a hole so big that it's empty again before you can even finish your lunch.

3. The Outbreak Test
During a real measles outbreak in 2010–2011, the researchers watched what happened. About half of the children with HIV who were exposed to the virus (or a booster shot) managed to "recharge" their buckets temporarily. But again, the water didn't stay; it leaked out again within about 2 years.

The Conclusion: We Need a "Double Seal"

The study concludes that starting HIV treatment early is great for the child's life, but it is not enough to stop measles.

Even if a baby gets HIV treatment at 2 months old and the measles vaccine at 9 months, their body still forgets the vaccine quickly.

The Recommendation:
Think of the measles vaccine as a coat of paint. For children with HIV, one coat isn't enough because it washes off. They need:

1. A second coat (Booster): They need a second dose of the vaccine much sooner than healthy kids.
2. A third coat: If the second dose is given too soon after starting HIV treatment, it might not stick well. They might need a third dose later in childhood.

In plain English:
Children with HIV are like houses with a weak foundation. Giving them medicine (cART) stops the foundation from crumbling, but it doesn't fix the roof. To keep the rain (measles) out, we need to keep putting up new tarps (vaccines) because the old ones fall off too fast. The doctors are saying, "Don't wait. Give them extra vaccines to keep them safe."

Technical Summary

1. Problem Statement

Children living with HIV (CHIV) face significant challenges in maintaining immunity to vaccine-preventable diseases like measles. While combination antiretroviral therapy (cART) reduces HIV-related morbidity and restores general immune function (primarily via naïve T-cell generation), it does not fully restore vaccine-induced immunity.

• The Gap: Historically, CHIV were often vaccinated before starting cART. However, global guidelines have shifted toward "test-and-treat" strategies, meaning many infants now initiate cART before receiving their first measles-containing vaccine (MCV1, typically given at 9 months).
• The Question: It is unclear whether initiating cART in infancy (prior to MCV1) allows for a robust measles antibody response compared to initiating cART later. Furthermore, the durability of any antibody response generated in this context remains poorly understood.

2. Methodology

The study was a retrospective analysis nested within two existing cohorts in Macha, Zambia (2007–2020):

• Study Population:
  • Cases: 301 CHIV from the Pediatric Antiretroviral Treatment (PART) study.
  • Controls: Age-matched HIV-uninfected community children from malaria surveillance studies (ICEMR).
• Grouping Strategy: CHIV were stratified by the timing of cART initiation relative to the presumed age of MCV1 (9 months):
  1. Early cART [0–8 months]: Initiated before MCV1.
  2. Late cART [9–23 months]: Initiated shortly after MCV1.
  3. Late cART [24–59 months]: Initiated well after MCV1.
• Laboratory Analysis:
  • Samples (plasma and dried blood spots) were tested for anti-measles IgG using Euroimmun ELISA.
  • Correction Factors: To address assay sensitivity and sample type discrepancies (plasma vs. DBS), results were adjusted using correction factors derived from comparisons with a Multiplex Bead Assay (MBA).
  • Seropositivity Threshold: Adjusted concentration $\ge$ 153 mIU/mL.
• Analytical Approaches:
  1. Cross-Sectional Analysis: Compared seroprevalence and antibody concentrations between CHIV groups and controls 6–12 months after cART initiation.
  2. Longitudinal Analysis (Post-MCV1 Decay): Used Bayesian growth mixture models to model antibody trajectories. The model assumed two latent groups: "non-responders" (no detectable response) and "decayers" (waning immunity). This estimated the probability of response and the time to seroreversion.
  3. Outbreak Analysis: Evaluated antibody boosts (seroconversion or $\ge$4-fold increase) during the 2010–2011 measles outbreak and subsequent supplemental immunization activities (SIA).

3. Key Contributions

• First Evidence of Early cART Impact: This is one of the few studies specifically evaluating measles immunity in CHIV who initiated cART before the standard 9-month measles vaccination window.
• Quantification of Waning Kinetics: The study utilized advanced Bayesian mixture modeling to estimate the specific rate of antibody decay and time to seroreversion in different cART initiation groups, moving beyond simple prevalence snapshots.
• Real-World Outbreak Data: The study incorporated longitudinal data from a natural measles outbreak (2010–2011) to assess immune boosting and subsequent decay in a high-exposure setting.

4. Key Results

A. Cross-Sectional Findings (Short-term)

• Low Seroprevalence: Only 31.9% of CHIV were seropositive 6–12 months after cART initiation.
• No Benefit of Early Initiation: There was no significant difference in seropositivity between the Early cART group (30.8%), the 9–23 month group (37.0%), and the 24–59 month group (26.6%).
• Comparison to Controls: In all groups, CHIV had significantly lower seroprevalence and antibody concentrations compared to age-matched HIV-uninfected controls (e.g., 30.8% vs. 63.5% in the 0–8 month group).

B. Longitudinal Findings (Antibody Decay)

• Non-Responders: Approximately 44–54% of CHIV were classified as "non-responders" (failing to mount a detectable antibody response to MCV1).
• Rapid Waning: Among those who did respond ("decayers"), antibody levels declined rapidly.
  • Time to Seroreversion: Estimated at 1.82 years for the Early cART group, 2.47 years for the 9–23 month group, and 3.23 years for the 24–59 month group.
  • Decay Rate: The Early cART group showed the fastest decay rate (-0.91 log units/year) compared to older initiation groups.
• Outbreak Response: During the 2010–2011 outbreak, 41.3% of CHIV seroconverted or boosted. However, the estimated time to seroreversion post-boost was still short (2.1 years).

C. Correlates

• Seropositivity was significantly associated with being an orphan and severe stunting, but not with the timing of cART initiation.
• Seropositivity varied by calendar year, likely reflecting exposure to wild-type virus or supplemental immunization activities (SIA).

5. Significance and Implications

• Revaccination Necessity: The study provides strong evidence that initiating cART in infancy does not guarantee durable measles immunity. Even with early treatment, CHIV remain susceptible to measles.
• Policy Recommendations:
  • Revaccination: CHIV, including those who started cART before 9 months, require a second dose of MCV (MCV2) to ensure protection.
  • Timing: If MCV2 is administered fewer than 6–9 months after cART initiation, protection may be suboptimal; a third dose may be necessary.
  • Monitoring: Given the rapid waning (2–3 years) observed even after natural infection (outbreak boosting), periodic revaccination or serological monitoring may be required for CHIV in high-risk settings.
• Global Health Context: These findings challenge the assumption that early immune reconstitution via cART is sufficient for vaccine-induced immunity. They support the need for tailored vaccination schedules for CHIV that differ from the general pediatric population, particularly in regions with high measles transmission risk.

Conclusion: The study concludes that low levels of measles antibodies persist among CHIV regardless of cART timing. To mitigate measles susceptibility and support regional elimination efforts, CHIV should be prioritized for MCV2 and potentially additional doses, with a recognition that their immunity wanes faster than that of HIV-uninfected peers.